Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Establishes International Influenza Network

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Scientists at leading public health agencies and research institutes collaborate to develop faster, more reliable flu subtyping methods.

Life Technologies Corporation has announced the establishment of the Global Influenza Network, a partnership including scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes in a collaborative effort to increase the speed and efficiency of influenza monitoring and vaccine development.

Members of the network are sharing tools, experience and data using the Ion Personal Genome Machine (PGM™) semiconductor sequencing platform.

"Life Technologies exhibited leadership in infectious disease tracking when our scientists worked alongside federal officials to identify the cause of H1N1 outbreak in 2008," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies.

Lucier continued, "We are very proud to now bring together a group of such distinguished organizations to tackle the continued threat of influenza worldwide."

Participating scientists include: Steve Glavas, head of the NGS Platform, and Mia Brytting, Ph.D., head of the microbial typing unit at the Swedish Institute for Communicable Disease Control (SMI); Gabriele Vaccari, Ph.D., researcher at the Istituto Superiore di Sanita in Rome; Mary Lea Killian, microbiologist at the U.S. National Veterinary Service Laboratories in Ames, Iowa; and David Wentworth at the J. Craig Venter Institute in Rockville, Md.

Partnership Develops Faster, More Reliable Flu Subtyping Methods
Annual seasonal influenza epidemics cause approximately 3 to 5 million cases of severe illness and 250,000 to 500,000 deaths, according to the World Health Organization (WHO).

Pandemics caused by novel influenza strains can result in staggering death tolls; the "Spanish flu" of 1918 is believed to have killed 40 million people, or 3 percent of the global population, according to the WHO.

Each year, public health agencies around the world collect samples from infected individuals and share data about flu subtypes circulating in their regions.

The pooled data are used by the WHO to determine the strains used to design a vaccine that will be effective against that year's epidemic. Costs of sequencing, however, have limited data set to about 20 percent of the patient samples collected.

"Using next generation sequencing technology makes whole influenza genome sequencing much easier, and much less expensive than older sequencing techniques, when used appropriately," said Glavas.

Scientists in the Global Influenza Network also believe that by sequencing all patient samples collected ahead of the flu season, they will be able to detect emerging strains earlier and focus resources on areas of the world where these strains are most prevalent in order to better contain new threats.

An additional benefit of semiconductor sequencing is the technologies' superior speed over conventional methods. Therefore, sequencing data can be collected in a smaller time window prior to vaccine production, which can also guide the production of vaccines so they more effectively target the strains most prevalent in the coming flu season.

"Now we can easily fully characterize influenza causing severe outbreaks," said Brytting.

Network Scientists Confirm Protocol's Accuracy and Economic
The current collaboration is a pilot program to evaluate the efficacy of influenza virus typing by semiconductor sequencing on Life Technologies' Ion Torrent platform, the Ion PGM™ sequencer.

After implementing Life Technologies' protocol for whole genome sequencing of Influenza A virus, the network partners determined it to be: (1) accurate; (2) highly sensitive and (3) economical (less than $100 per isolate) because it enables scientists to multiplex at least 10 samples in a single run on the Ion PGM™ sequencer.

Global Influenza Network partners have agreed to share their data and experiences in order to refine the initial protocol, if needed. The results of the collaborative study will be submitted to a peer-reviewed research journal for publication.

The Ion Personal Genome Machine (PGM™) is Research Use Only and not intended for use in diagnostic procedures.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences
Agreement formed for the development of potent siRNA therapeutics in China.
Thursday, June 20, 2013
Life Technologies Announces First Quarter 2013 Results
Revenue increased 2.5% to $963 million.
Friday, May 03, 2013
Life Technologies Acquires BAC BV
The acquisition expands Life Technologies capabilities and product offerings in biopharmaceutical research and manufacturing.
Tuesday, January 22, 2013
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!